We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Expression Levels Measured in a Variety of Sample Types

By LabMedica International staff writers
Posted on 12 Nov 2009
A quantitative nuclease protection assay (qNPA) process will be applied microarrays to enable rapid and efficient measuring of gene expression levels in a variety of sample types.

Roche NimbleGen (Madison, WI, USA) and High Throughput Genomics (HTG; Tucson, AZ, USA), provider of the quantitative nuclease protection assay (qNPA), have entered into a supply agreement. Roche NimbleGen will provide HTG with high-density, multiplex DNA microarray slides for advanced gene-expression analysis. HTG will apply the company's quantitative nuclease-protection assay (qNPA) process to the microarrays to enable rapid and accurate measurements of the gene-expression levels in a variety of sample types.

The agreement enhances HTG's existing service capability offering with the ability to take a broader look at gene expression through the multiplex capability of the Roche NimbleGen microarrays. Sample preparation using qNPA technology allows for a much simpler, more cost-effective workflow versus traditional labeling methods, while the Roche NimbleGen multiplex technology offers a cost-effective high-density microarray providing in depth gene-expression information.

Gerd Maass, CEO of Roche NimbleGen said, "The partnership with HTG showcases the strengths of the two companies and the flexibility of the NimbleGen Arrays by pairing two innovative technologies to provide flexibility, time savings, and cost savings while offering the significant in depth genetic information that our high-density arrays provide."

Roche NimbleGen, Inc. is a manufacturer and supplier of a suite of DNA microarrays, consumables, instruments, and services. NimbleGen's Maskless Array Synthesis (MAS) technology uses digital light to produce high-density arrays of long oligo probes that provide information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. Scientists can thus obtain a clearer understanding of genomic and epigenomic structure and function and how they impact medicine and biology.

Related Links:

Roche NimbleGen
High Throughput Genomics



New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
Hematology Consumables
Bioblood Devices

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
12 Nov 2009  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
12 Nov 2009  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
12 Nov 2009  |   Industry



PURITAN MEDICAL